+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

EpiReview: Meningococcal disease in NSW, 1991-2011: trends in relation to meningococcal C vaccination



EpiReview: Meningococcal disease in NSW, 1991-2011: trends in relation to meningococcal C vaccination



New South Wales Public Health Bulletin 24(3): 119-124



To review the epidemiology of invasive meningococcal disease in NSW for the period 1991-2011, in particular since the introduction of the meningococcal C vaccination program in 2003. We undertook a descriptive analysis of NSW notifications of invasive meningococcal disease for the period 2003-2011, and explored long-term changes in the epidemiology of invasive meningococcal disease over the period 1991-2011. In the period 2003-2011, there were 1009 notifications of invasive meningococcal disease in NSW, an average annual rate of 1.6 per 100000 population. Notification rates were highest in the 0-4 and 15-19-year age groups (8.5 and 3.6 per 100000 population respectively). In the period 1991-2011, invasive meningococcal disease notifications increased between 1991 and 2000, peaking at 3.8 notifications per 100000 population in 2000. Notifications have decreased since that time to 1.0 per 100000 population in 2011, most markedly for serogroup C disease since the introduction of the meningococcal C vaccination program in 2003. Meningococcal C notifications reduced from 54 in 2002 (0.8 per 100000 population) to two in 2011 (0.03 per 100000 population). Meningococcal C deaths have also decreased, from nine in 2002 to zero in 2011. The greatest reduction in meningococcal C notifications has been in those aged 1-19 years, the target group for the vaccination program. Meningococcal B notifications have also decreased over the study period, however serogroup B remains the predominant serogroup for invasive meningococcal disease in NSW. Notification rates of invasive meningococcal disease have decreased in NSW since 2000. Rates of serogroup C disease have decreased since the introduction of the meningococcal C vaccination program in 2003. Most of the burden of invasive meningococcal disease in NSW is now due to serogroup B disease.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 053004175

Download citation: RISBibTeXText

PMID: 24360208


Related references

Meningococcal disease in New South Wales 1991-1999: EpiReview. New South Wales Public Health Bulletin 11(7): 128-130, 2002

Chemoprophylaxis and vaccination in preventing subsequent cases of meningococcal disease in household contacts of a case of meningococcal disease: a systematic review. Epidemiology and Infection 143(11): 2259-2268, 2015

Meningococcal disease in catalonia 1 year after mass vaccination campaign with meningococcal group C polysaccharide vaccine. Infection 31(6): 392-397, 2003

Epidemiology of invasive meningococcal disease in Germany, 2002-2010, and impact of vaccination with meningococcal C conjugate vaccine. Journal of Infection 66(1): 48-56, 2013

Dramatic decline of serogroup C meningococcal disease in Catalonia (Spain) after a mass vaccination campaign with meningococcal C conjugated vaccine. Vaccine 21(7-8): 729-733, 2003

Emergency Meningococcal ACWY Vaccination Program for Teenagers to Control Group W Meningococcal Disease, England, 2015-2016. Emerging Infectious Diseases 23(7): 1184-1187, 2017

Meningococcal carriage, meningococcal disease and vaccination. Journal of Infection 16(1): 55-59, 1988

Seasonal variation in meningococcal disease in Denmark: relation to age and meningococcal phenotype. Scandinavian Journal of Infectious Diseases 35(4): 226-229, 2003

The changing epidemiology of meningococcal disease in Quebec, Canada, 1991-2011: potential implications of emergence of new strains. Plos One 7(11): E50659, 2013

Complement factor 7 gene mutations in relation to meningococcal infection and clinical recurrence of meningococcal disease. Molecular Immunology 47(4): 671-677, 2010

Influence of prior meningococcal C polysaccharide vaccination on the response and generation of memory after meningococcal C conjugate vaccination in young children. Journal of Infectious Diseases 184(3): 377-380, 2001

Licensure of a meningococcal conjugate vaccine for children aged 2 through 10 years and updated booster dose guidance for adolescents and other persons at increased risk for meningococcal disease--Advisory Committee on Immunization Practices (ACIP), 2011. Mmwr. Morbidity and Mortality Weekly Report 60(30): 1018-1019, 2011

Meningococcal Carriage Following a Vaccination Campaign With MenB-4C and MenB-FHbp in Response to a University Serogroup B Meningococcal Disease Outbreak-Oregon, 2015-2016. Journal of Infectious Diseases 216(9): 1130-1140, 2017

Laboratory-confirmed invasive meningococcal disease: effect of the Hajj vaccination policy, Saudi Arabia, 1995 to 2011. Euro Surveillance 18(37):, 2013

Meningococcal vaccination in patients with C7 deficiency enhances neutrophil mediated meningococcal killing. Program & Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 33: 151, 1993